CD34+ cells from human umbilical cord blood were purified by Dynal beads M-450 CD34 immunoselection system and cultured in the presence of various cytokines alone or in combination, including stem cell factor (SCF), i...CD34+ cells from human umbilical cord blood were purified by Dynal beads M-450 CD34 immunoselection system and cultured in the presence of various cytokines alone or in combination, including stem cell factor (SCF), interleukin-6 (IL-6) and erythropoietin (EPO). The results revealed that: (D In methylcellulose culture, the plating efficiencies of purified cord blood CD34+ cells were much different when stimulated by various cytokines. IL-6 alone had the lowest colo-ny yield, while the combination of SCF, IL-6 and EPO had the highest yield. ② In the suspension culture, IL-6 alone or IL-6 + EPO had little expanding effect on cord blood CD34+ celis, the other cytokine combinations could expand cord blood CD34+ celis at different Ievels. Among them, the combination of SCF, IL-6 and EPO had the maximal expanding effect on cord blood CD34+ celis, the number of progenitor celis peaked at day 21, about 29-fold increase and nucleated celis increased approximately 3676-fold at day 28. The expanding effect of展开更多
心血管损伤与修复依赖于多种细胞的募集、增殖与分化。CD34^(+)细胞作为一类以分化簇34(cluster of differentiation34,CD34)蛋白为标志物的异质性细胞群体,长期被视为心血管再生与修复的关键靶点。该类细胞可展现出高度的异质性与多向...心血管损伤与修复依赖于多种细胞的募集、增殖与分化。CD34^(+)细胞作为一类以分化簇34(cluster of differentiation34,CD34)蛋白为标志物的异质性细胞群体,长期被视为心血管再生与修复的关键靶点。该类细胞可展现出高度的异质性与多向分化潜能,在特定的微环境信号调控下,能够分化为内皮细胞、平滑肌细胞、成纤维细胞、炎症细胞等多种谱系,在内皮修复、组织纤维化、免疫调节等过程中发挥重要作用。在心血管疾病中CD34^(+)细胞可介导双重调控作用:既能促进组织修复与再生,又可能加剧病理损伤。尽管CD34^(+)细胞疗法在心血管疾病中已具有良好的治疗潜力,但其向临床转化的过程仍面临诸多挑战与瓶颈。基于此,该文系统梳理了CD34^(+)细胞的来源、分化轨迹与功能异质性,总结其在心血管基础研究与临床转化中的最新进展,旨在为深化疾病机制理解、开发新型精准治疗策略提供新视角。展开更多
To clarify the hematopoietic potential of various sub-classes of human hematopoietic progenitor cells, we used a multicolor staining protocol in conjunction with anti-CD34 and -CD38 McAb. We characterized two cell fra...To clarify the hematopoietic potential of various sub-classes of human hematopoietic progenitor cells, we used a multicolor staining protocol in conjunction with anti-CD34 and -CD38 McAb. We characterized two cell fractions in CD34+cells with or without CD38 expression. A clonogenic assay showed that most CFC were present in CD34+CD38+ population. Morphologic analysis showed that blast-like cells were more enriched in the CD34+CD38 fraction. To clarify the biologic differences between both fractions, we examined the more primitive progenitor cell function by assessing long-term culture-initiating cells (LTC-IC) on the stromal cells. At the first two weeks, more CF.C harvested from the culture in the fractions initiated with both populations. However, more LTC-IC were present during weeks 4 to 12 in the CD34+CD38- population. These results indicate the primitive progenitors are more enriched in CD34+CD38 population than in CD34+CD38+ cells.展开更多
Hepatocellular carcinoma(HCC),which is essentially primary liver cancer,is closely related to CD8^(+)T cell immune infiltration and immune suppression.We constructed a CD8^(+)T cells related risk score model to predic...Hepatocellular carcinoma(HCC),which is essentially primary liver cancer,is closely related to CD8^(+)T cell immune infiltration and immune suppression.We constructed a CD8^(+)T cells related risk score model to predict the prognosis of HCC patients and provided therapeutic guidance based on the risk score.Using integrated bulk RNA sequencing(RNA-seq)and single-cell RNA sequencing(scRNA-seq)datasets,we identified stable CD8^(+)T cell signatures.Based on these signatures,a 3-gene risk score model,comprised of KLRB1,RGS 2,and TNFRSF1B was constructed.The risk score model was well validated through an independent external validation cohort.We divided patients into high-risk and low-risk groups according to the risk score and compared the differences in immune microenvironment between these two groups.Compared with low-risk patients,high-risk patients have higher M2-type macrophage content(P<0.0001)and lower CD8^(+)T cells infiltration(P<0.0001).High-risk patients predict worse response to immunotherapy treatment than low-risk patients(P<0.01).Drug sensitivity analysis shows that PI3K-β inhibitor AZD6482 and TGFβRII inhibitor SB505124 may be suitable therapies for high-risk patients,while the IGF-1R inhibitor BMS-754807 or the novel pyrimidine-based anti-tumor metabolic drug Gemcitabine could be potential therapeutic choices for low-risk patients.Moreover,expression of these 3-gene model was verified by immunohistochemistry.In summary,the establishment and validation of a CD8^(+)T cell-derived risk model can more accurately predict the prognosis of HCC patients and guide the construction of personalized treatment plans.展开更多
为探讨人参总皂甙(totalsaponins of panaxginseng,TSPG)协同造血生长因子体外诱导CD34+造血干/祖细胞(HSC/HPC)扩增与分化的作用,收集人脐血、骨髓细胞并采用StemsepTM干细胞分选系统分离纯化CD34+HSC/HPC,用不同剂量TSPG加入不同组合...为探讨人参总皂甙(totalsaponins of panaxginseng,TSPG)协同造血生长因子体外诱导CD34+造血干/祖细胞(HSC/HPC)扩增与分化的作用,收集人脐血、骨髓细胞并采用StemsepTM干细胞分选系统分离纯化CD34+HSC/HPC,用不同剂量TSPG加入不同组合的造血生长因子进行培养,检测细胞总数、CD34+细胞和CD33+细胞比例及集落形成细胞总数(CFC)、粒系祖细胞(CFU-GM)数量变化。结果显示:10-70μg/mlTSPG均可不同程度地提高脐血细胞总数、CFC数和CD34+细胞数,50μg/ml是最佳刺激浓度,可使细胞总数、CFC数和CD34+细胞数分别增至(2470.5±79.96)×103、(53.96±4.29)×100%和(21.86±3.09)×100%;20μg/ml是液体培养诱导骨髓CD34+细胞向粒系分化的最佳浓度,可使细胞总数、CFU-GM和CD33+细胞分别增至(133.2±9.03)×103、(26.78±1.91)×100%和(16.98±1.73)×100%;甲基纤维素半固体培养检测显示,TSPG(10-50μg/ml)均能提高CD34+细胞形成CFU-GM的集落产率,以TSPG20μg/ml效果最为明显。结论:合适剂量的TSPG能够促进CD34+造血干/祖细胞体外扩增与定向诱导分化。展开更多
文摘CD34+ cells from human umbilical cord blood were purified by Dynal beads M-450 CD34 immunoselection system and cultured in the presence of various cytokines alone or in combination, including stem cell factor (SCF), interleukin-6 (IL-6) and erythropoietin (EPO). The results revealed that: (D In methylcellulose culture, the plating efficiencies of purified cord blood CD34+ cells were much different when stimulated by various cytokines. IL-6 alone had the lowest colo-ny yield, while the combination of SCF, IL-6 and EPO had the highest yield. ② In the suspension culture, IL-6 alone or IL-6 + EPO had little expanding effect on cord blood CD34+ celis, the other cytokine combinations could expand cord blood CD34+ celis at different Ievels. Among them, the combination of SCF, IL-6 and EPO had the maximal expanding effect on cord blood CD34+ celis, the number of progenitor celis peaked at day 21, about 29-fold increase and nucleated celis increased approximately 3676-fold at day 28. The expanding effect of
文摘心血管损伤与修复依赖于多种细胞的募集、增殖与分化。CD34^(+)细胞作为一类以分化簇34(cluster of differentiation34,CD34)蛋白为标志物的异质性细胞群体,长期被视为心血管再生与修复的关键靶点。该类细胞可展现出高度的异质性与多向分化潜能,在特定的微环境信号调控下,能够分化为内皮细胞、平滑肌细胞、成纤维细胞、炎症细胞等多种谱系,在内皮修复、组织纤维化、免疫调节等过程中发挥重要作用。在心血管疾病中CD34^(+)细胞可介导双重调控作用:既能促进组织修复与再生,又可能加剧病理损伤。尽管CD34^(+)细胞疗法在心血管疾病中已具有良好的治疗潜力,但其向临床转化的过程仍面临诸多挑战与瓶颈。基于此,该文系统梳理了CD34^(+)细胞的来源、分化轨迹与功能异质性,总结其在心血管基础研究与临床转化中的最新进展,旨在为深化疾病机制理解、开发新型精准治疗策略提供新视角。
文摘To clarify the hematopoietic potential of various sub-classes of human hematopoietic progenitor cells, we used a multicolor staining protocol in conjunction with anti-CD34 and -CD38 McAb. We characterized two cell fractions in CD34+cells with or without CD38 expression. A clonogenic assay showed that most CFC were present in CD34+CD38+ population. Morphologic analysis showed that blast-like cells were more enriched in the CD34+CD38 fraction. To clarify the biologic differences between both fractions, we examined the more primitive progenitor cell function by assessing long-term culture-initiating cells (LTC-IC) on the stromal cells. At the first two weeks, more CF.C harvested from the culture in the fractions initiated with both populations. However, more LTC-IC were present during weeks 4 to 12 in the CD34+CD38- population. These results indicate the primitive progenitors are more enriched in CD34+CD38 population than in CD34+CD38+ cells.
基金国家自然科学基金项目(No.81902513)山西省应用基础研究计划项目(No.202303021211114 and 202103021224228)山西省高等教育百亿工程“科技引导”专项(No.BYJL047)资助。
文摘Hepatocellular carcinoma(HCC),which is essentially primary liver cancer,is closely related to CD8^(+)T cell immune infiltration and immune suppression.We constructed a CD8^(+)T cells related risk score model to predict the prognosis of HCC patients and provided therapeutic guidance based on the risk score.Using integrated bulk RNA sequencing(RNA-seq)and single-cell RNA sequencing(scRNA-seq)datasets,we identified stable CD8^(+)T cell signatures.Based on these signatures,a 3-gene risk score model,comprised of KLRB1,RGS 2,and TNFRSF1B was constructed.The risk score model was well validated through an independent external validation cohort.We divided patients into high-risk and low-risk groups according to the risk score and compared the differences in immune microenvironment between these two groups.Compared with low-risk patients,high-risk patients have higher M2-type macrophage content(P<0.0001)and lower CD8^(+)T cells infiltration(P<0.0001).High-risk patients predict worse response to immunotherapy treatment than low-risk patients(P<0.01).Drug sensitivity analysis shows that PI3K-β inhibitor AZD6482 and TGFβRII inhibitor SB505124 may be suitable therapies for high-risk patients,while the IGF-1R inhibitor BMS-754807 or the novel pyrimidine-based anti-tumor metabolic drug Gemcitabine could be potential therapeutic choices for low-risk patients.Moreover,expression of these 3-gene model was verified by immunohistochemistry.In summary,the establishment and validation of a CD8^(+)T cell-derived risk model can more accurately predict the prognosis of HCC patients and guide the construction of personalized treatment plans.
文摘为探讨人参总皂甙(totalsaponins of panaxginseng,TSPG)协同造血生长因子体外诱导CD34+造血干/祖细胞(HSC/HPC)扩增与分化的作用,收集人脐血、骨髓细胞并采用StemsepTM干细胞分选系统分离纯化CD34+HSC/HPC,用不同剂量TSPG加入不同组合的造血生长因子进行培养,检测细胞总数、CD34+细胞和CD33+细胞比例及集落形成细胞总数(CFC)、粒系祖细胞(CFU-GM)数量变化。结果显示:10-70μg/mlTSPG均可不同程度地提高脐血细胞总数、CFC数和CD34+细胞数,50μg/ml是最佳刺激浓度,可使细胞总数、CFC数和CD34+细胞数分别增至(2470.5±79.96)×103、(53.96±4.29)×100%和(21.86±3.09)×100%;20μg/ml是液体培养诱导骨髓CD34+细胞向粒系分化的最佳浓度,可使细胞总数、CFU-GM和CD33+细胞分别增至(133.2±9.03)×103、(26.78±1.91)×100%和(16.98±1.73)×100%;甲基纤维素半固体培养检测显示,TSPG(10-50μg/ml)均能提高CD34+细胞形成CFU-GM的集落产率,以TSPG20μg/ml效果最为明显。结论:合适剂量的TSPG能够促进CD34+造血干/祖细胞体外扩增与定向诱导分化。
